- Home
- CBIO vs NXDT Comparison
CBIO vs NXDT Comparison
Compare CBIO & NXDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- NXDT
- Stock Information
- Founded
- CBIO 2003
- NXDT 2012
- Country
- CBIO United States
- NXDT United States
- Employees
- CBIO N/A
- NXDT N/A
- Industry
- CBIO
- NXDT Investment Managers
- Sector
- CBIO
- NXDT Finance
- Exchange
- CBIO Nasdaq
- NXDT Nasdaq
- Market Cap
- CBIO 209.8M
- NXDT 170.0M
- IPO Year
- CBIO N/A
- NXDT N/A
- Fundamental
- Price
- CBIO $12.35
- NXDT $3.13
- Analyst Decision
- CBIO Strong Buy
- NXDT
- Analyst Count
- CBIO 5
- NXDT 0
- Target Price
- CBIO $25.60
- NXDT N/A
- AVG Volume (30 Days)
- CBIO 111.3K
- NXDT 133.6K
- Earning Date
- CBIO 11-23-2025
- NXDT 01-01-0001
- Dividend Yield
- CBIO N/A
- NXDT 9.66%
- EPS Growth
- CBIO N/A
- NXDT N/A
- EPS
- CBIO N/A
- NXDT 0.99
- Revenue
- CBIO N/A
- NXDT N/A
- Revenue This Year
- CBIO N/A
- NXDT N/A
- Revenue Next Year
- CBIO N/A
- NXDT N/A
- P/E Ratio
- CBIO N/A
- NXDT $6.41
- Revenue Growth
- CBIO N/A
- NXDT N/A
- 52 Week Low
- CBIO $9.81
- NXDT $5.89
- 52 Week High
- CBIO $21.40
- NXDT $13.07
- Technical
- Relative Strength Index (RSI)
- CBIO 49.46
- NXDT 34.05
- Support Level
- CBIO $12.30
- NXDT $3.35
- Resistance Level
- CBIO $12.84
- NXDT $3.66
- Average True Range (ATR)
- CBIO 0.72
- NXDT 0.14
- MACD
- CBIO 0.07
- NXDT -0.02
- Stochastic Oscillator
- CBIO 66.55
- NXDT 9.77
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.